Icure Pharmaceutical Incorporation (KOSDAQ:175250)
South Korea
· Delayed Price · Currency is KRW 1,920.00
-57.00 (-2.88%)
At close: May 12, 2025, 3:30 PM KST
KOSDAQ:175250 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 69,207 | 56,806 | 59,367 | 64,283 | 90,144 | Upgrade
|
| Other Revenue | -0 | -0 | - | 0 | - | Upgrade
|
| Revenue | 69,207 | 56,806 | 59,367 | 64,283 | 90,144 | Upgrade
|
| Revenue Growth (YoY) | 21.83% | -4.31% | -7.65% | -28.69% | 47.97% | Upgrade
|
| Cost of Revenue | 61,600 | 55,508 | 64,947 | 69,086 | 72,165 | Upgrade
|
| Gross Profit | 7,607 | 1,298 | -5,580 | -4,804 | 17,979 | Upgrade
|
| Selling, General & Admin | 17,097 | 15,234 | 11,826 | 16,425 | 26,883 | Upgrade
|
| Research & Development | 2,796 | 3,685 | 4,242 | 2,419 | 3,046 | Upgrade
|
| Other Operating Expenses | 484.92 | 486.93 | 522.68 | 394.27 | 507.27 | Upgrade
|
| Operating Expenses | 25,599 | 29,023 | 21,507 | 25,316 | 33,513 | Upgrade
|
| Operating Income | -17,992 | -27,725 | -27,087 | -30,119 | -15,534 | Upgrade
|
| Interest Expense | -5,109 | -5,689 | -7,279 | -5,420 | -3,065 | Upgrade
|
| Interest & Investment Income | 320.57 | 785.09 | 1,309 | 949.41 | 881.81 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 5,787 | Upgrade
|
| Currency Exchange Gain (Loss) | -18.48 | 36.21 | -6.69 | 98.32 | -20.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,135 | 1,587 | -4,377 | 2,214 | -188.19 | Upgrade
|
| EBT Excluding Unusual Items | -21,664 | -31,006 | -37,441 | -32,278 | -12,139 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,457 | 660.36 | -4,287 | -3,388 | 1,207 | Upgrade
|
| Gain (Loss) on Sale of Assets | 31,657 | 51.52 | -70.11 | 490.69 | -547.22 | Upgrade
|
| Asset Writedown | -8,791 | - | -1,292 | -3,040 | -18.29 | Upgrade
|
| Other Unusual Items | -134.18 | -2,231 | - | -619.46 | - | Upgrade
|
| Pretax Income | -388.49 | -32,525 | -43,090 | -38,835 | -11,498 | Upgrade
|
| Income Tax Expense | -413.23 | -226.49 | -541.28 | -450.58 | 652.62 | Upgrade
|
| Earnings From Continuing Operations | 24.73 | -32,299 | -42,549 | -38,384 | -12,150 | Upgrade
|
| Minority Interest in Earnings | 1,025 | 878.84 | 782.11 | 217.51 | -463.78 | Upgrade
|
| Net Income | 1,049 | -31,420 | -41,766 | -38,167 | -12,614 | Upgrade
|
| Net Income to Common | 1,049 | -31,420 | -41,766 | -38,167 | -12,614 | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 23 | 22 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 23 | 22 | 20 | Upgrade
|
| Shares Change (YoY) | - | 61.23% | 7.58% | 9.71% | 8.69% | Upgrade
|
| EPS (Basic) | 27.94 | -836.56 | -1792.96 | -1762.57 | -639.10 | Upgrade
|
| EPS (Diluted) | 27.94 | -837.00 | -1793.00 | -1763.00 | -639.17 | Upgrade
|
| Free Cash Flow | -19,077 | -15,744 | -15,479 | -31,929 | -35,399 | Upgrade
|
| Free Cash Flow Per Share | -507.93 | -419.20 | -664.50 | -1474.52 | -1793.49 | Upgrade
|
| Gross Margin | 10.99% | 2.28% | -9.40% | -7.47% | 19.95% | Upgrade
|
| Operating Margin | -26.00% | -48.81% | -45.63% | -46.85% | -17.23% | Upgrade
|
| Profit Margin | 1.52% | -55.31% | -70.35% | -59.37% | -13.99% | Upgrade
|
| Free Cash Flow Margin | -27.57% | -27.72% | -26.07% | -49.67% | -39.27% | Upgrade
|
| EBITDA | -9,206 | -18,682 | -18,872 | -22,341 | -8,510 | Upgrade
|
| EBITDA Margin | -13.30% | -32.89% | -31.79% | -34.75% | -9.44% | Upgrade
|
| D&A For EBITDA | 8,786 | 9,043 | 8,216 | 7,778 | 7,024 | Upgrade
|
| EBIT | -17,992 | -27,725 | -27,087 | -30,119 | -15,534 | Upgrade
|
| EBIT Margin | -26.00% | -48.80% | -45.63% | -46.85% | -17.23% | Upgrade
|
| Advertising Expenses | 26.32 | 123.77 | 138.03 | 1,266 | 1,917 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.